Results 111 to 120 of about 2,265 (188)

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022 : An Analysis of the International Severe Asthma Registry [PDF]

Acknowledgments The authors thank all the ISAR collaborators (Appendix 1) and study participants, and Ekaterina Maslova of AstraZeneca for her contributions to the study design.
Altraja, Alan, Bergeron , Celine, Bourdin, Arnaud, Carter, Victoria, Christoff, George C, Cook, Bill, Erhard, Clement, EVEREST Study Working Group, Katial, Rohit, Koh, Mariko Siyue, Le, Tham T, Lehtimäki, Lauri, Mahboub, Bassam, Martin, Neil, Papadopoulos, Nikolaos G, Perez-De-Llano, Luis, Pfeffer, Paul E, Price, David, Quinton, Anna, Rhee, Chin Kook, Tran, Trung N   +20 more
core   +2 more sources

TSLP‐targeting therapy: Beyond allergy?

Clinical and Translational Medicine, 2023
Risa Ebina‐Shibuya, Warren J. Leonard
doaj   +1 more source

Reply to Lipworth and Chan [PDF]

, 2023
Brusselle, Guy, Riemann, Sebastian
core   +2 more sources

ERS International Congress 2023:highlights from the Airway Diseases Assembly [PDF]

In this review, early career and senior members of Assembly 5 (Airway Diseases, Asthma, COPD and Chronic Cough) present key recent findings pertinent to airway diseases that were presented during the European Respiratory Society International Congress ...
Baker, James, Beech, Augusta, Bergantini, Laura, Bossios, Apostolos, Braunstahl, Gert Jan, Conemans, Lennart H., Lombardi, Francesco, Mathioudakis, Alexander G., Pobeha, Pavol, Ricciardolo, Fabio Luigi Massimo, Romero, Leidy Paola Prada, Schleich, Florence, Snelgrove, Robert J., Trinkmann, Frederik, Uller, Lena   +14 more
core   +1 more source

Is Tezepelumab effective in treatment of chronic rhinosinusitis with nasal Polyps?

The Egyptian Journal of Otolaryngology
Background Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory condition of the paranasal sinuses and nasal cavities, which affects 5% to 28% of the general population and can have a profound impact on quality of life.
Mohamed M. Thabit, Hesham A. El-Sersy, Tarek A. Hamdy, Mohammed Aleem   +3 more
doaj   +1 more source

Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma

Respiratory Research
Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment ...
Nina Vincent-Galtié, Quentin Marquant, Emilie Catherinot, Felix Ackermann, Antoine Magnan, Colas Tcherakian, Matthieu Groh   +6 more
doaj   +1 more source

Treatment of COPD with a particular focus on biological therapy: a systematic review [PDF]

Incroduction and aim. COPD is a heterogeneous condition characterized by persistent respiratory symptoms. These symptoms can significantly reduce the quality of life for patients. The conventional treatment used so far is not always effective, especially
Cieplińska, Aleksandra, Kuzio, Agnieszka, Ziojła, Kinga   +2 more
core   +1 more source

A Scoping Review: Comparison of Tezepelumab and Mepolizumab in the Treatment of Persistent Severe Asthma

Uncontrolled moderate to severe asthma is a disease process that persists despite the maximum therapy of either oral corticosteroids OCS or inhaled corticosteroids (ICS) and long-acting B2 agonists (LABA)1,4 .
Liaw, Alex
core  

Novel Real-World Insights Into Tezepelumab Effectiveness in Steroid-Dependent Asthma. [PDF]

J Asthma Allergy
Aslam MMS, Senn R, Bagheri A, Harwood H, Troost JP, Lugogo NL, Mohan A.   +6 more
europepmc   +1 more source

Curr Allergy Asthma Rep [PDF]

Purpose of ReviewTo discuss the effectiveness of biologics, some of which comprise the newest class of asthma controller medications, and non-biologics in the treatment of asthma co-existing with obesity.Recent FindingsOur review of recent preliminary ...

core